Search results
1 mar 2022 · EDTA is an intravenous chelating agent with high affinity to divalent cations (lead, cadmium, and calcium) that may be beneficial in the treatment of cardiovascular disease (CVD). Although a large randomized clinical trial showed benefit, smaller studies were inconsistent.
Chelation therapy is a process in which a substance is delivered intravenously (through the veins) to bind metals or minerals so they can be removed from the body via urination. When it’s used as a complementary treatment for heart disease, a course of treatment can require 20 to 40 weekly infusions lasting several hours each.
Key findings. Twenty-four studies (15 prospective studies, 5 retrospective case series, 4 randomized clinical trials) assessed repeated ethylenediaminetetra-acetic acid (EDTA) chelation treatment in patients with preexistent cardiovascular disease.
The off-label use of chelation therapy (disodium edetate or EDTA) for prevention of cardiovascular disease (CVD) is widespread, despite the lack of convincing evidence for efficacy or approval from the Food and Drug Administration.
26 lut 2016 · Chelation therapy reduced the risk of cardiovascular events by 18% (hazard ratio [HR] = 0.82; 95% confidence interval [CI], 0.69-0.99; p = 0.035; Figure 1), with a 5-year number needed to treat (NNT) of 18 patients to prevent an event. 9 Continued separation between the two curves at the completion of the study suggested a sustained effect of ...
Chelation therapy is promoted and practiced around the world as a form of alternative medicine in the treatment of atherosclerotic cardiovascular disease. It has been suggested as a safe, relatively inexpensive, non‐surgical method of restoring blood flow in atherosclerotic vessels.
2 mar 2022 · Repeated EDTA for CVD treatment may provide more benefit to patients with diabetes and severe peripheral arterial disease. Differences across infusion regimens, including dosage, solution components, and number of infusions, limit comparisons across studies.
